2016. CONSTRUCT

OL RT/ IFX vs cicloscporin/ ASUC

Open label, pragmatic, randomised controlled trial. Patients with acute severe UC failing to IV hydrocortisone within 5 days were randomized to:

- IFX 5mg/kg (0,2,6) or ciclosporin 2mg/kg/d for 7 days and then oral for 12 weeks.

After 12 w all treatment was at the discretion of physician.

<u>Primary endpoint:</u> quality-adjusted survival over at least a year


Results:

- No differences in the quality-adjusted survival between groups.
- No differences in the secondary outcomes.
- No differences in time to colectomy or in rates of colectomy 41% on IFX vs 48% on ciclosporin.
- No differences in serious adverse events

Conclusions:

There was no significant difference between ciclosporin and infliximab in clinical effectiveness.

Infliximab versus ciclosporin for steroid-resistant acute severe UC(CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial



Williams JG et al. Lancet Gastroenterol Hepatol. 2016; 1 (1): 15-24